FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC By Ogkologos - March 18, 2026 162 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR 4,000 Cancer Patients Affected by Diluted Chemotherapy Doses from Crooked Pharmacist September 17, 2020 Maximizing the Prospects for Progress Against Cancer June 11, 2018 The IGCCCG Update Model Allows Improved and More Granular Individual Prognostic... April 16, 2021 Government update on the Clinical Research Vision: More needed to go... June 30, 2022 Load more HOT NEWS Aspirin Being Investigated as Possible Treatment for Triple Negative Breast Cancer Seeing a Promising Future for Progress against Childhood Cancer Study Suggests Watching Disney Movies May Improve Quality of Life for... Common anti-inflammatory drug could boost cancer immunotherapy
